First-in-Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of Pirepemat, a Cortical Enhancer, in Healthy Volunteers

Erik Rein-Hedin1,2, Folke Sjöberg1,3, Susanna Waters4, Clas Sonesson4, Nicholas Waters4, Fredrik Huss1,2, and Joakim Tedroff4,5

Abstract

Pirepemat (IRL752) is a cortical enhancer being developed for the prevention of falls in patients with Parkinson disease. This first-in-human, randomized, double-blind, placebo-controlled phase 1 study evaluated safety, tolerability, and pharmacokinetics (PK) of pirepemat administered as oral single ascending doses (10, 35, 75, 175, 350 mg) and multiple ascending doses (100 and 250 mg 3 times daily) for 7 days to healthy male volunteers. Twenty and 24 subjects were randomly assigned in the single ascending dose and multiple ascending doses parts of the study, respectively. Pirepemat was generally well tolerated, although an increased frequency of adverse events of mild intensity within nervous system disorders (headache and dizziness) was seen after administration of 350 mg as a single dose and after multiple doses of 100 and 250 mg. PK of pirepemat showed a linear relationship over the dose range studied and exhibited dose proportionality after multiple-dose administration. Accumulation after 7 days of multiple dosing was minor. Absorption was rapid, with a median time to maximum concentration of 2.0 hours on day 1 and day 7 (100 and 250 mg) and a mean terminal half-life between 3.7 and 5.2 hours. Food intake had no (obvious) impact on PK. The results support 3-times-daily dosing and further clinical development.

Keywords

first-in-human, healthy volunteers, Parkinson disease, pharmacokinetics, pirepemat

The first symptoms of Parkinson disease (PD) are typically motor symptoms such as tremor, muscle rigidity, and slowness of movement. However, nonmotor features of PD are prominent in this complex neurologic disease, with symptoms worsening as the disease progresses.1 In late stages of PD, nonmotor features include a range of symptoms from autonomic dysfunction and dysphagia to dementia and emotional problems.1,2 With advancement of the disease, axial motor symptoms may also come to dominate the motor presentation.3 While levodopa is the most widely used treatment for PD, late-stage axial motor symptoms and nonmotor symptoms are generally levodopa resistant and contribute significantly to disability and morbidity.2

Axial symptoms in the form of postural instability and freezing of gait are strongly associated with decreased mobility and frequent falls and correlate

1 CTC Clinical Trial Consultants AB, Uppsala, Sweden
2 Department of Surgical Sciences, Plastic Surgery, Uppsala University, Uppsala, Sweden
3 Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden
4 Integrative Research Laboratories Sweden AB, Gothenburg, Sweden
5 Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Submitted for publication 8 March 2021; accepted 10 April 2021.

Corresponding Author:
Erik Rein-Hedin, MD, CTC Clinical Trial Consultants AB, Dag Hammarståls väg 108, 752 37, Uppsala, Sweden
(e-mail: erik.rein-hedin@surgsci.uu.se)
Correlation between other motor symptoms and nigral dopaminergic impairment has previously been shown but less so with postural instability. Similarly to nonmotor features such as cognitive impairment, postural instability and falls are not reversible with dopaminergic therapy. Axial motor deterioration and cognitive function are further interconnected, with a possible cause being PD patients’ use of attentive strategies to compensate for postural dysfunction.

Several nondopaminergic neuropathologic features that might account for these symptoms have been identified in PD, including loss of neurons causing norepinephrine and acetylcholine deficiency. It is reasonable to think that symptoms resistant to dopaminergic treatment are associated with deficient cortical neurotransmission, albeit underlying pathologies are believed to be heterogeneous and related to complex interactions among cortical neurotransmitters.

Pirepemat (Figure 1), (3S)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine (also known as IRL752), is a cortical enhancer being developed to treat postural dysfunction and cognitive impairment in PD. Pirepemat was discovered by a process referred to as the integrative screening process and belongs to a class of compounds that elicit regional preference for increases in catecholamine (dopamine and norepinephrine) levels in the frontal cortex. The pharmacologic profile of pirepemat has been found to be consistent with a cortically regioselective facilitatory impact on cortical neurotransmission, as well as cognitive impairment–reversing features. In vitro neurotarget affinity and functional data suggest 5-hydroxytryptamine 7 receptor and α2C-adrenoceptor antagonism are key contributors to the in vivo efficacy profile of pirepemat.

In vivo pharmacokinetics (PK) of pirepemat in rats and dogs is characterized by complete and rapid absorption, wide tissue distribution including the central nervous system, and log-linear elimination. Pirepemat is eliminated through a combination of renal excretion of the parent compound and metabolic transformation involving cytochrome P450 (CYP) oxidations and formation of glucuronide conjugates. In vitro CYP reaction phenotyping was done by established methods (Admescope Ltd, Oulu, Finland) using 8 recombinant human isozymes. The results revealed that CYP2A6, CYP2B6, and CYP2D6 metabolize pirepemat by oxidations. However, only CYP2A6 and CYP2B6 gave rise to the main observed human plasma metabolites, M11b and M12, whereas CYP2D6 mainly metabolized pirepemat to M11a, which is found as a minor metabolite in human plasma (Integrative Research Laboratories Sweden AB, data on file). Uridine 5′-diphosphoglucuronosyltransferase reaction phenotyping has not been done.

The objective of this first-in-human study in healthy volunteers was to assess safety, tolerability, and PK of single (SADs) and multiple ascending doses (MADs) of pirepemat, to support further clinical development. Furthermore, this study aimed to use an adaptive design and integrated protocol to increase learning without undermining the safety or quality of the study.

**Method**

**Study Design**

The study (EudraCT 2015-004479-61) was approved by the Regional Ethics Review Board in Uppsala (as of 2019 part of the Swedish Ethical Review Authority) and was conducted at CTC Clinical Trial Consultants AB (Uppsala, Sweden). Informed consent was provided by all subjects before participation in any study-related procedures.

This was a first-in-human, randomized, double-blind, placebo-controlled, phase 1 study evaluating the safety, tolerability, and PK of SADs and MADs of pirepemat in healthy male volunteers. The study was designed and conducted per the Declaration of Helsinki and International Conference on Harmonization/Good Clinical Practice guidelines. The study consisted of SAD and MAD parts. Planned enrollment for both parts was 40 subjects (actual enrollment was 44 subjects due to withdrawals and replacements). Pirepemat (fumarate salt) and placebo were administered as oral capsules and were of identical appearance (capsule strengths 10, 25, and 50 mg pirepemat free base, corresponding to 15.4, 38.6, and 77.2 mg fumarate salt). Capsules were swallowed with 240 mL of tap water. All doses in the SAD part were administered in the fasted condition except for the third-dose period for cohort 2.

The SAD part consisted of 2 cohorts (1 and 2) of 8 subjects. An alternate panel design with within-subject dose escalation was used, where subjects received sequentially increasing oral doses. Within each cohort, subjects were randomized to receive pirepemat or placebo in different sequences (Table 1). At each dose level, 6 subjects received pirepemat and 2 subjects received placebo in a 3:1 ratio. A sentinel dosing strategy was used in all SAD cohorts, where 2 subjects were initially dosed (1 pirepemat, 1 placebo) and closely...
Table 1. Dosing Schedule—SAD Part

| Cohort/Dose | Sequence Number | Cohort 1 Dose 1 | Cohort 2 Dose 1 | Cohort 1 Dose 2 | Cohort 2 Dose 2 | Cohort 1 Dose 3 | Cohort 2 Dose 3 |
|-------------|----------------|----------------|----------------|----------------|----------------|----------------|----------------|
| Cohort 1 (n = 8) | 1:1 (n = 2) | Placebo | 75 mg | 350 mg | | |
| | 1:2 (n = 2) | 10 mg | 75 mg | Placebo | | |
| | 1:3 (n = 2) | 10 mg | 75 mg | 350 mg | | |
| | 1:4 (n = 2) | 10 mg | Placebo | 350 mg | | |
| Cohort 2 (n = 8) | 2:1 (n = 2) | Placebo | 175 mg | 175 mg | | |
| | 2:2 (n = 2) | 35 mg | 175 mg | 175 mg | | |
| | 2:3 (n = 2) | 35 mg | 175 mg | Placebo | | |
| | 2:4 (n = 2) | 35 mg | Placebo | 175 mg | | |

SAD, single ascending dose.

*aStandardized breakfast meal given within 60 minutes before pirepemat/placebo administration.

observed for 24 hours before proceeding to dose remaining subjects.

SAD cohort 1 received 10-, 75-, and 350-mg pirepemat or placebo. SAD cohort 2 received 35-, 175- (fasted), and 175-mg (after a standardized breakfast) pirepemat or placebo. The standardized high-fat, high-calorie breakfast consisted of eggs, bacon, rösti (potato pancake), 2 slices of bread with butter, 1 glass (2.3 dL) of whole milk, and coffee or tea. Single doses for individual subjects were separated by a washout period of at least 2 weeks. There was an interval of at least 1 week between each dose level to allow time for safety data and PK to be reviewed by a safety review committee. Subjects were confined to the research clinic from the evening before each dosing until 24 hours after dosing (8 hours for the food-effect period) and, with the exception of the 10-mg level, returned 48 hours after dosing for PK sampling. A follow-up visit was conducted for each cohort 5 to 10 days after dosing.

In the MAD part of the study, subjects were administered oral doses of pirepemat or placebo 3 times daily for 7 consecutive days. Two cohorts (1 and 2) of 12 subjects were included. Nine subjects in each cohort received pirepemat, and 3 subjects received placebo in a 3:1 ratio. MAD cohort 1 and cohort 2, respectively, received 100- or 250-mg pirepemat (or matching placebo) 3 times daily. At the 250-mg dose level, sentinel dosing was used. There was an interval of at least 1 week between cohorts to allow time for safety data and PK to be reviewed. Subjects participating in the MAD part were confined to the research clinic from the evening before the first dosing until 24 hours following the last dose on day 7. A follow-up visit was conducted 5 to 10 days after the last dose.

Dose Selection

The starting dose was based on allometric scaling/human equivalent dose calculations, as determined by toxicology studies in rats and dogs. A starting dose of 10 mg corresponded to <5% of the estimated no-observed-adverse-effect level in the most sensitive species and <25% of the predicted pharmacologically active dose.

Based on PK and safety data from the SAD part and exposures in preclinical studies, it was estimated that 100 and 250 mg administered 3 times daily would cover pharmacologically relevant plasma exposures within a safe range in terms of safety margins as determined in the toxicity studies.

Study Population

Healthy male volunteers aged 18 to 50 years and with a body mass index of 18 to 30 kg/m² were included. All subjects were in good health, as determined at the screening visit and with no history of clinically significant disease or disorder. Subjects were nonusers of nicotine products and with no use of concomitant medication. For the MAD part, 2 validated questionnaires (Generalized Anxiety Disorder 7-item scale and Patient Health Questionnaire) were used at screening so as not to include subjects with pronounced symptoms of anxiety or depression.

Safety Assessments

Safety assessments for both parts comprised recording adverse events (AEs), physical examinations, 12-lead electrocardiograms, vital signs (blood pressure, heart rate, body temperature), and clinical laboratory measurements. In the SAD part, continuous electrocardiogram telemetry was used for cardiac surveillance up to 24 hours after each dose. In the MAD part, vital signs also included respiratory rate and the Columbia-Suicide Severity Rating Scale was used to assess suicidal thoughts and behaviors before the first dose and before leaving the clinic after the last dose. AEs were coded according to the Medical Dictionary for
Regulatory Activities (MedDRA) version 19.0, and the grading of AEs followed Common Terminology Criteria for Adverse Events version 4.03, also taking into account the safety grading system proposed by Sibille et al.17

Pharmacokinetic Assessments and Methods
Venous blood samples were collected for determination of pirepemat concentrations. In the SAD part, samples were collected before dosing and at multiple time points (20 minutes; 40 minutes; and 1, 2, 3, 4, 6, 8, 10, and 12 hours) during the day of dosing, as well as 24 (8 for food-effect period) and 48 (except for 10-mg period) hours after dosing. In the MAD part, PK samples were collected before the first dose and before the morning dose, respectively, on days 1 and 7 and at multiple time points (20 minutes; 40 minutes; and 1, 2, 3, 4, 5, 6, 8, 12 hours [day 7], and 14 hours) during days 1 and 7. The last PK sample was obtained 24 hours after the morning dose on day 7.

The PK assessments were performed using pirepemat (supplied by Syntagon AB, Södertälje, Sweden) as the reference material and as internal standard IRL.921 x oxalate [pirepemat-d3 x oxalate] (supplied by Integrative Research Laboratories Sweden AB, Gothenburg, Sweden). Samples for determination of pirepemat concentrations in plasma were analyzed by the Swedish National Veterinary Institute (Uppsala, Sweden), by means of a validated liquid chromatography–tandem mass spectrometry method. Samples were thawed, vortex mixed, and centrifuged. To 100 μL of study sample, 100 μL of acetonitrile:water (1:9) and 600 μL of precipitation solution containing internal standard were added, before being injected into a chromatographic system. Instrumentation consisted of an Acquity UPLC system coupled to a Xevo-TQ-S tandem quadrupole mass spectrometer (Waters Corp., Milford, Massachusetts). A positive electrospray ionization technique was used. The chromatographic column was Waters Acquity UPLC BEH C18 (50×2.1 mm length × inner diameter, particle diameter 1.7 μm). Mobile phases consisted of (1) 0.1% formic acid in water and (2) 0.1% formic acid in acetonitrile. The total run time was 2.0 minutes including washing and equilibration of the column. The auto-sampler was programmed to inject 1.0 μL of sample. Multiple reaction monitoring mass transitions were m/z 214/182 and m/z 217/182 for pirepemat and its internal standard, respectively. The molecular weight of pirepemat is 213.2 g/mol. Calibration curves for pirepemat ranged from 12.0 to 12,000 nM (2.6–2600 ng/mL) in human plasma, and the lower limit of quantitation in plasma was 12.0 nM using 100-μL sample volume.

A total of 1158 human plasma samples were analyzed in 33 accepted runs on 17 different days. All runs fulfilled the quality control (QC) criteria stating that at least two-thirds of the QC samples in each run must have determined concentration values within 15% of their respective nominal values and at least 1 QC sample for each level must have a determined value within this interval. In each run, at least three-quarters of the calibration samples had to be within 15% of their nominal values when back-calculated (except for the lowest point, which may differ 20%). Within-run mean accuracy (% bias) ranged from −1.9% to 2.8%, and precision (% coefficient of variation [CV]) was ≤4.71%. Between-run mean accuracy (% bias) ranged from −1.0% to 1.7% and precision (%CV) was ≤5.80%.

PK analyses were conducted using noncompartmental analysis with Phoenix WinNonlin version 6.3 or higher (Pharsight Corp., Certara Inc., Princeton, New Jersey). PK parameters included terminal half-life (t1/2), maximum plasma concentration (Cmax), time to Cmax (tmax), area under the plasma concentration–time curve (AUC) from time zero to infinity (AUC0-<infty>), AUC from time 0 to last time with quantifiable concentration (AUCt), and AUC during a dose interval at steady state (AUCss [AUC0-6h on day 7 MAD]), terminal elimination rate constant, and total apparent clearance of drug from plasma.

Statistical Analysis
Statistical calculations were performed using SAS Version 9.4 (SAS Institute Inc., Cary, North Carolina). The statistical analyses include descriptive statistics reflecting the explorative nature of the study. No formal sample size calculation was performed for this study. The size of the cohorts/dose groups was considered sufficient to provide adequate information on the safety and PK parameters for the purposes of this study.

The data for subjects receiving placebo are presented pooled across groups.

Continuous data were summarized by cohort/dose group using descriptive statistics. Relative bioavailability after fed and fasting conditions was determined from AUC from time 0 to 8 hours and Cmax after the corresponding 175-mg doses in cohort 2. Values were log-transformed (natural logarithm).

Dose proportionality and the proportional constant was estimated using the random coefficients model: log(\text{parameter}) = \log(a) + S + (b + k) * \log(\text{dose}) where a is a constant, S is a random intercept, b is the proportional constant, and k is the random slope effect. The accumulation ratio for each subject was calculated by taking the AUCss on day 7 of dosing, divided by AUC0-6h for the first dose interval during day 1.

Results
Demographics
In total, 44 male subjects were enrolled in the study (Table 2). Twenty subjects were enrolled in the SAD part (2 subjects in each SAD cohort were withdrawn
Table 2. Demographics and Baseline Characteristics—SAD and MAD Parts

|                  | SAD Cohort 1 (n = 10) | SAD Cohort 2 (n = 10) | SAD Total (n = 20) | MAD 100 mg (n = 9) | MAD 250 mg (n = 9) | MAD Placebo (n = 6) | MAD Total (n = 24) |
|------------------|------------------------|------------------------|--------------------|-------------------|-------------------|-------------------|-------------------|
| Age, y, mean (SD)| 27.4 (6.1)             | 29.4 (8.7)             | 28.4 (7.4)         | 33.4 (11.0)       | 32.9 (11.4)       | 31.5 (11.0)       | 32.8 (10.7)       |
| Sex, n (%)       |                        |                        |                    | Male 9 (100)      | 9 (100)           | 6 (100)           | 24 (100)          |
| Ethnicity, n (%) |                        |                        |                    | Hispanic or Latino 1 (10) | 1 (10) | 2 (10) | 1 (11.1) | 1 (11.1) | 6 (100) | 6 (100) | 4 (42) |
|                  |                        |                        |                    | Not Hispanic or Latino 9 (90) | 9 (90) | 18 (90) | 8 (88.9) | 8 (88.9) | 6 (100) | 23 (95.8) |          |
| Weight, kg, mean (SD) | 75.12 (8.88)          | 75.16 (9.76)           | 75.14 (9.08)       | 82.3 (11.3)       | 81.9 (8.6)        | 82.0 (15.3)       | 82.1 (11.0)       |
| Height, cm, mean (SD) | 176.3 (9.3)           | 176.3 (9.3)            | 177.6 (7.1)        | 182.4 (8.0)       | 182.9 (9.3)       | 179.4 (7.8)       | 181.8 (8.2)       |
| BMI, kg/m², mean (SD) | 23.5 (2.9)            | 24.2 (2.7)             | 23.8 (2.7)         | 24.8 (3.1)        | 24.5 (2.6)        | 25.3 (3.5)        | 24.8 (2.9)        |

BMI, body mass index; MAD, multiple ascending dose; SAD, single ascending dose; SD, standard deviation.

and replaced due to withdrawal of consent) and 24 subjects in the MAD part. One subject in SAD cohort 1 received only 2 doses before being withdrawn and not replaced due to an AE not related to study treatment. Mean age among subjects participating in the SAD part was 28.4 years and in the MAD part 32.8 years. No major differences across cohorts or dose groups were seen.

Safety and Tolerability

In the SAD part, a total of 22 treatment-emergent adverse events (TEAEs) were reported by 8 subjects (Table 3). The number of subjects experiencing any TEAE in relation to 10, 35, 75, 175, and 350 mg pirepemat and placebo was 2, 2, 2, 1, 4, and 2, respectively. Of the TEAEs reported, 12 of 22 (54.5%) occurred after administration of 350-mg pirepemat. Most events (16/22; 72.7%) were assessed as not related to study treatment, and 19 of 22 (86.4%) were of mild intensity. One subject experienced 2 serious adverse events (SAEs) assessed as not related to study treatment 6 days after administration with 350-mg pirepemat (see below). One AE assessed as not related to study treatment led to withdrawal.

In the MAD part, a total of 22 TEAEs were reported, and 20 of 22 (90.9%) were of mild intensity. No severe events were reported. No SAEs occurred, and no AEs led to withdrawal. TEAEs were experienced in all dose groups, including placebo. The proportion of subjects experiencing any TEAE at doses of 100 mg and 250 mg and placebo was 2 of 9 (22.2%), 6 of 9 (66.7%), and 2 of 6 (33.3%), respectively. Following administration of 100-mg pirepemat, 4 of 6 AEs reported (66.7%) were assessed as at least possibly related to study treatment, and 8 of 12 AEs (66.7%) following administration of 250 mg were assessed as at least possibly related. All events after placebo administration were assessed as not related.

During both SAD and MAD, the most frequently represented TEAEs were nervous system disorders (headache and dizziness being the most frequently reported events). One subject in SAD cohort 1 experienced 2 SAEs (concussion following syncope) assessed as not related to study treatment 6 days after the 350-mg dose. The subject presented with nasopharyngitis the day after the last dose (350 mg), followed by mild pyrexia. Six days after the last dose, he fainted while brushing his teeth at night and hit his head, developing a concussion. He was hospitalized for observation but did not require any treatment or intervention. It was revealed that he had once before experienced a similar episode of syncope while having a viral infection. One subject was withdrawn due to mild hypertension assessed as not related to study treatment before the planned third single dose. The last single dose administered before withdrawal was placebo.

In the MAD part of the study, there were no SAEs or withdrawals. One subject in the 100-mg dose group presented with transient moderate hypertension after
Table 3. Summary of number of subjects reporting TEAEs—SAD and MAD Parts

|        | SAD          |          |          |          |          | Placebo | Total |
|--------|--------------|----------|----------|----------|----------|---------|-------|
|        | 10 mg (n = 6) | 35 mg (n = 6) | 75 mg (n = 6) | 175 mg (n = 6) | 175 mg (n = 5) | 350 mg (n = 12) | Total (n = 20) |
| Headache | 0            | 1 (16.7) | 1 (16.7) | 0          | 0          | 3 (60.0) | 0      | 4 (20.0) |
| Dizziness | 0            | 0        | 0        | 0          | 0          | 2 (40.0) | 0      | 2 (10.0) |
| Presyncope | 0            | 1 (16.7) | 0        | 0          | 0          | 0        | 0      | 1 (5.0)  |
| Syncope | 0            | 0        | 0        | 0          | 0          | 1 (20.0) | 0      | 1 (5.0)  |
| Nasopharyngitis | 2 (33.3) | 0        | 1 (16.7) | 0          | 0          | 2 (40.0) | 1 (8.3) | 3 (15.0) |
| Pyrexia | 0            | 0        | 0        | 0          | 0          | 1 (20.0) | 0      | 1 (5.0)  |
| Concussion | 0            | 0        | 0        | 0          | 0          | 1 (20.0) | 0      | 1 (5.0)  |
| Nervousness | 0            | 0        | 0        | 0          | 0          | 1 (20.0) | 0      | 1 (5.0)  |
| Epistaxis | 0            | 0        | 0        | 1 (16.7) | 0          | 0        | 0      | 1 (5.0)  |
| Hypertension | 0            | 0        | 0        | 0          | 0          | 1 (8.3) | 0      | 1 (5.0)  |

MAD, multiple ascending dose; SAD, single ascending dose.

Variants are presented as n (%).

aStandardized breakfast meal given within 60 minutes before pirepemat. Each subject can be counted more than once in this table.

the first dose on day 3. The study drug was interrupted and resumed the next morning on day 4 without recurrence of hypertension. Increase of hepatic enzyme values was reported at the follow-up visit for 1 subject treated with multiple doses of 250 mg. There were no other clinically significant abnormalities involving laboratory values, electrocardiograms, or physical examinations.

Pharmacokinetics

For the dose range 10- to 350-mg pirepemat (single dose, fasted) the mean t1/2 ranged from 3.4 to 3.9 hours, and tmax was approximately 2 hours. The mean plasma concentration increased with increasing single doses (Figure 2; Table 4). When pirepemat was given in the fed condition, the median tmax was 3.0 hours. Four subjects received 175-mg pirepemat under both fasted and fed conditions. The geometric mean ratio (fed/fasted) was 99.8% (90% confidence interval [CI], 84.96-117.13) for AUC from time 0 to 8 hours and 99.7% (90%CI, 80.71-123.18) for Cmax.

Analysis of dose linearity after single dosing for AUC0-inf and AUCt showed a linear relationship with a proportionality constant of 1.13 (90%CI, 1.07-1.19) for AUC0-inf and 1.17 (90%CI, 1.11-1.22) for AUCt, indicating exposure slightly greater than dose proportional, with 90%CI above and not including 1.0. Dose linearity based on Cmax after single dosing was not possible due to too many likelihood evaluations. Following multiple dosing, the proportionality constants for AUCss and Cmax were 1.18 (90%CI, 0.97-1.40) and 1.11 (90%CI, 0.94-1.29), respectively, with 90%CI including 1.0.

The mean accumulation ratio (AUC0-6h,Day 7/AUC0-6h,Day 1) after 7 days of dosing was 1.31 (standard deviation, 0.17) for 100 mg and 1.33 (standard deviation, 0.20) for 250 mg, suggesting only minor accumulation from first to last dose.

Discussion

There is an unmet medical need for PD patients with symptoms resistant to dopamine replacement therapy. Pirepemat is a first-in-class, small-molecule cortical enhancer, increasing noradrenaline and dopamine as well as immediate early genes including activity-regulated cytoskeleton-related protein mRNA in the frontal
Figure 2. Mean plasma pirepemat concentration-time plots for the SAD part, by treatment. Semilogarithmic scale. Dotted line represents the lower limit of quantification of 2.6 ng/mL (12 nmol/L). For 10 mg, all 24-hour PK samples were below limit of quantification. For 175 mg fed (after standardized breakfast), last PK sample taken was 8 hours after dosing. PK, pharmacokinetic; SAD, single ascending dose.

Arc is a key regulator of synaptic plasticity, triggered by synaptic N-methyl-D-aspartate receptor-related mechanisms and implicated in memory-related processes and cognitive functions. The results of this study enabled a recently published phase 2a study with pirepemat in patients, where exploratory analysis of efficacy outcomes indicated a possible effect on predominant symptoms in advanced stages of PD.

Study Design

This first-in-human study was conducted with the primary aim to evaluate safety and tolerability of single and multiple ascending doses of pirepemat when administered to healthy male subjects. An integrated protocol was used, combining SAD and MAD as well as drug-food interaction. Protocols that combine more than 1 element in early clinical trials have now become common practice. Integrated protocols are considered to be time saving and cost efficient as compared to conducting separate trials. Generally, increased trial complexity might nevertheless increase the number of substantial amendments due to interim result requirements or other warranted substantial changes based on emerging data.

This protocol allowed for an adaptive approach. Dose escalation between cohorts was guided by the recommendations from the safety review committee, based on available safety, tolerability, and PK data. A defined decision-making process outlined dose levels for the MAD part based on results from the SAD part. However, a substantial amendment between the SAD and MAD parts was required due to unexpected PK results. Initially, once-daily administration of pirepemat/placebo for 10 days was planned for the MAD part. Preliminary PK data from the SAD part showed that exposures achieved after single doses were lower than predicted from animal data, with $t_{1/2}$ being shorter than expected. Based on these findings and available safety data, the dosing regimen was revised, and a substantial amendment was submitted to allow for 3-times-daily dosing for 7 days.

In the SAD part, an alternate panel/crossover design was used where each of the 2 cohorts received every other dose. During the dosing of each cohort, the other was in washout. As a result, substantially fewer subjects were required. It has previously been concluded that an alternate panel design can be preferable over sequential panel designs in assessing dose proportionality and can increase first-in-human trial efficiency without
Table 4. Pharmacokinetic Parameters After SADs and MADs of Pirepemat

### SAD

| Parameter       | 10 mg (n = 6) | 35 mg (n = 6) | 75 mg (n = 6) | 175 mg (n = 6) | 175a mg (n = 6) | 350 mg (n = 5) |
|-----------------|--------------|--------------|--------------|---------------|----------------|--------------|
| t_{1/2}, h      | Mean (SD)    | 3.7 (0.9)    | 3.6 (0.6)    | 3.4 (0.9)     | 3.9 (0.2)      | 3.8 (0.4)     | 3.9 (0.5)    |
| t_{max}, h      | Median (min-max) | 2.0 (0.7-2.0) | 2.0 (0.7-2.0) | 2.0 (1.0-2.2) | 1.5 (1.0-2.0)  | 3.0 (1.0-4.0) | 2.0 (1.0-2.2) |
| C_{max}, ng/mL  | Mean (SD)    | 25.5 (7.55)  | 108 (22.0)   | 224 (110)     | 620 (112)      | 568 (140)     | 1130 (248)   |
|                 | Geometric mean (%CV) | 24.3 (37.4)  | 106 (19.5)   | 206 (43.6)    | 612 (17.5)     | 554 (25.1)    | 1110 (25.6)  |
| AUC_{0-6h}, ng * h/mL | Mean (SD) | 172 (74.1)  | 705 (181)    | 1290 (610)    | 4510 (1060)    | 4400 (1290)   | 7750 (2340)  |
|                 | Geometric mean (%CV) | 160 (44.3)  | 687 (24.9)   | 1180 (49.3)   | 4420 (23.0)    | 4280 (28.6)   | 7380 (39.6)  |
| CL/F, L/h       | Mean (SD)    | 67.2 (28.1)  | 52.2 (12.3)  | 69.3 (30.7)   | 40.5 (8.7)     | 41.9 (11.0)   | 50.7 (23.4)  |
|                 | Geometric mean (%CV) | 62.5 (44.3)  | 51.0 (24.9)  | 63.5 (49.3)   | 39.6 (23.0)    | 40.9 (28.6)   | 47.5 (39.6)  |

### MAD

| Parameter       | 100 mg Day 1 (n = 9) | Day 7 (n = 9) | 250 mg Day 1 (n = 9) | Day 7 (n = 9) |
|-----------------|----------------------|--------------|----------------------|--------------|
| t_{1/2}, h      | Mean (SD)            | 3.7 (0.9)    | 3.9 (1.0)            | 4.2 (0.7)    | 5.2 (1.9)    |
| t_{max}, h      | Median (min-max)     | 2.0 (0.4-4.0) | 2.0 (0.7-4.0)     | 2.0 (0.7-5.0) | 2.0 (1.0-4.0) |
| C_{max}, ng/mL  | Mean (SD)            | 257 (43.0)   | 327 (58.8)           | 701 (144)    | 911 (194)    |
|                 | Geometric mean (%CV) | 254 (17.7)   | 322 (18.2)           | 688 (21.0)   | 893 (21.5)   |
| AUC_{0-6h}, ng * h/mL | Mean (SD) | 1050 (156)   | 1340 (245)           | 2930 (577)   | 4020 (1020)  |
|                 | Geometric mean (%CV) | 1040 (15.2)  | 1320 (18.8)         | 2870 (20.1)  | 3910 (25.7)  |
| CL/F, L/h       | Mean (SD)            | 57.9 (16.1)  | 76.7 (14.6)          | 49.2 (11.6)  | 65.7 (16.4)  |
|                 | Geometric mean (%CV) | 56.2 (27.3)  | 75.5 (18.8)         | 48.1 (23.2)  | 63.9 (25.7)  |

AUC_{0-6h}, area under the curve from time zero to 6 hours after dosing; AUC_{0-inf}, area under the plasma concentration-time curve from time zero to infinity; AUC_{t}, area under the curve from time zero to last time with quantifiable concentration; C_{max}, maximum plasma concentration; CL/F, total apparent clearance of drug from plasma; %CV, geometric coefficient of variation (%); MAD, multiple ascending dose; SAD, single ascending dose; SD, standard deviation; t_{1/2}, terminal half-life; t_{max}, time of occurrence of C_{max};

*Standardized breakfast meal given within 60 minutes before pirepemat and last pharmacokinetic sample taken was 8 hours after dosing.

compromising on safety concerns. We demonstrate that an alternate panel design where placebo administration rotates among subjects, demands fewer subjects while maintaining the benefits of including placebo treatment. Even so, alternate panel designs have been less frequent in first-in-human studies in healthy volunteers, and to our knowledge they still are.

Two subjects in each SAD cohort were replaced after the first treatment period due to withdrawal of consent, and 1 subject was withdrawn due to an AE and not replaced (AE was unrelated to study treatment). A total of 15 subjects completed the SAD part of the study. All 24 subjects randomized in the MAD part completed the study. Including delay due to submission and regulatory
approvals of the substantial amendment, time between first-subject-first-visit and last-subject-last-visit was 9 months and 5 days.

Since no data on reproductive toxicology was available, only males were recruited. Given the short duration of study participation, including women and women of childbearing potential could possibly have been considered, taking sufficient precautions to prevent pregnancy.

**Safety and Tolerability**

Overall, pirepemat was well tolerated at single doses up to 350 mg and multiple doses up to 250 mg 3 times daily for 7 days. An increased frequency of central nervous system–related AEs, headache, and dizziness, was seen at the highest SAD dose level (350 mg) and during treatment with multiple doses of pirepemat, as compared to placebo. These AEs were transient and mild in intensity.

The 2 associated SAEs reported during the follow-up period (syncope and concussion) occurred in the same subject in SAD cohort 1 and was not assessed as related to the study drug.

One single event of hypertension was reported for 1 subject receiving multiple doses of 100 mg. An ad hoc evaluation by the safety review committee was made, leading to a temporary interruption of treatment. The event was assessed as related to the study treatment, though the subject recovered; treatment was resumed the next day and hypertension did not reoccur for the remainder of the study. There were no other cardiovascular AEs in the study. Transient increase of hepatic enzymes was observed for 1 subject in the 250-mg MAD cohort at the follow-up visit with alanine aminotransferase 3.05 times the upper limit of normal (ULN) and aspartate aminotransferase 3.85 times the ULN. Subject’s baseline values were also above the ULN.

In the recent phase 2a study in patients with PD, pirepemat was administered for 28 days. AEs were consistent with findings in this study, with predominantly mild and transient central nervous system–related AEs during the first 2 weeks and a few patients with transient and reversible mild to moderate increases in liver enzymes following discontinuation of treatment. 21

**Pharmacokinetics**

For the dose range tested, pirepemat was rapidly absorbed and eliminated from plasma. For subjects receiving pirepemat both under fasted and fed conditions, no (obvious) food interaction was observed. Timing of drug intake in relation to food intake was concluded to be of less importance for the MAD part. Supra-proportional exposure (AUC) was seen following single-dose administration based on AUCₙₙ and Cₘₐₓ after multiple-dose administration. Accumulation after 7 days was minor.

**Conclusions**

Single and multiple doses of pirepemat were generally well tolerated in healthy male volunteers. The safety, tolerability, and PK profiles of this first-in-human study support 3-times-daily dosing and further clinical development.

**Acknowledgments**

The authors thank Jan Erik Berglund, MD, PhD, for acting as principal investigator of the study; Bengt Dahlström, PhD, and Boel Löfberg, PhD, for input on analysis and interpretation of PK data; Johanna Anttila, MSc, for acting as study director for the bioanalytical part of the study; all research team members; and all participating volunteers.

**Conflicts of Interest**

S.W., C.S., N.W., and J.T. are supported by Integrative Research Laboratories Sweden AB (salary) and are stockholders of IRLAB Therapeutics AB. E.R.H., F.S., and F.H. declare no conflicts of interest.

**Funding**

The study was funded by Integrative Research Laboratories Sweden AB, Gothenburg, Sweden.

**Data-Sharing Statement**

Data will be available from the corresponding author on reasonable request.

**References**

1. Langston JW. The Parkinson’s complex: parkinsonism is just the tip of the iceberg. *Ann Neurol*. 2006;59(4):591-596.
2. Kalia LV, Lang AE. Parkinson’s disease. *The Lancet*. 2015;386(9996):896-912.
3. Hely MA, Reid WGJ, Adena MA, Halliday GM, Morris JGL. The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. *Mov Disord Off J Mov Disord Soc*. 2008;23(6):837-844.
4. Jankovic J. Parkinson’s disease: clinical features and diagnosis. *J Neurol Neurosurg Psychiatry*. 2008;79(4):368-376.
5. Hallett M, Poewe W. *Therapeutics of Parkinson’s Disease and Other Movement Disorders*. Hoboken, NJ: John Wiley & Sons; 2008.
6. Vingerhoets FJ, Schulzer M, Calne DB, Snow BJ. Which clinical sign of Parkinson’s disease best reflects the nigrostriatal lesion? *Ann Neurol*. 1997;41(1):58-64.
7. Koller WC, Glatt S, Vetere-Overfield B, Hassanein R. Falls and Parkinson's disease. *Clin Neuropharmacol*. 1989;12(2):98-105.
8. Morris M, Iansek R, Smithson F, Huxham F. Postural instability in Parkinson’s disease: a comparison with and without a concurrent task. *Gait Posture*. 2000;12(3):205-216.
9. Braak H, Tredici KD, Rüb U, de Vos RAI, Jansen Steur ENH, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. *Neurobiol Aging*. 2003;24(2):197-211.
10. Buddhala C, Loftin SK, Kuley BM, et al. Dopaminergic, serotonergic, and noradrenergic deficits in Parkinson disease. *Ann Clin Transl Neurol*. 2015;2(10):949-959.
11. Goldman JG, Holden S. Treatment of psychosis and dementia in Parkinson’s disease. *Curr Treat Options Neurol*. 2014;16(3):281.
12. Waters S, Svensson P, Kullingsjö J, et al. In vivo systems response profiling and multivariate classification of CNS active compounds: a structured tool for CNS drug discovery. *ACS Chem Neurosci*. 2017;8(4):785-797.
13. Hjorth S, Waters S, Waters N, et al. (3S)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine (IRL752)—a novel cortical-preferring catecholamine transmission-and cognition-promoting agent. *J Pharmacol Exp Ther*. 2020;374(3):404-419.
14. Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. *Arch Intern Med*. 2006;166(10):1092-1097.
15. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. *J Gen Intern Med*. 2001;16(9):606-613.
16. Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. *Am J Psychiatry*. 2011;168(12):1266-1277.
17. Sibille M, Patat A, Caplain H, Donazzolo Y. A safety grading scale to support dose escalation and define stopping rules for healthy subject first-entry-into-man studies: some points to consider from the French Club Phase I working group. *Br J Clin Pharmacol*. 2010;70(5):736-748.
18. Bramham CR, Alme MN, Bittins M, et al. The Arc of synaptic memory. *Exp Brain Res*. 2010;200(2):125-140.
19. McIntyre CK, Miyashita T, Setlow B, et al. Memory-influencing intra-basolateral amygdala drug infusions modulate expression of Arc protein in the hippocampus. *Proc Natl Acad Sci U S A*. 2005;102(30):10718-10723.
20. Guzowski JF, Lyford GL, Stevenson GD, et al. Inhibition of activity-dependent arc protein expression in the rat hippocampus impairs the maintenance of long-term potentiation and the consolidation of long-term memory. *J Neurosci*. 2000;20(11):3993-4001.
21. Svenningsson P, Odin P, Dizdar N, et al. A phase 2a trial investigating the safety and tolerability of the novel cortical enhancer IRL752 in Parkinson's disease dementia. *Mov Disord Off J Mov Disord Soc*. 2020;35(6):1046-1054.
22. Erb-Zohar K, Sourgens H, Breithaupt-Groegler K. Use of integrated clinical trial protocols—a survey in early medicines development. *Int J Clin Pharmacol Ther*. 2018;56(5):205-211.
23. Fruhner K, Hartmann G, Sudhop T. Analysis of integrated clinical trial protocols in early phases of medicinal product development. *Int J Clin Pharmacol Ther*. 2001;39(6):1065-1078.
24. Yin Y, Chen C. Optimizing first-time-in-human trial design for studying dose proportionality. *Drug Inf J*. 2001;35(10):1065-1078.
25. Agyeman A, Ofori-Asenso R. First in human trials: are there any benefits of including placebo treatments? *Drug Dev Ther*. 2016;7:73.
26. Buoen C, Bjerrum OJ, Thomsen MS. How first-time-in-human studies are being performed: a survey of phase I dose-escalation trials in healthy volunteers published between 1995 and 2004. *J Clin Pharmacol*. 2005;45(10):1123-1136.